Search
Dexchlorpheniramine
go.drugbank.com/drugs/DB13679InvestigationalIt is an antihistamine drug with anticholinergic (drying) and sedative actions. It disrupts histamine signaling by competing with histamine for cell receptor sites on effector cells.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 InhibitorsBertilimumab
go.drugbank.com/drugs/DB05429InvestigationalBertilimumab is a fully human anti-eotaxin monoclonal antibody with potential in the treatment of allergic disorders, has moved into pre-clinical development. It is developed by MedImmune for the treatment of Allergic Rhinitis.
Omapatrilat
go.drugbank.com/drugs/DB00886ExperimentalThis drug from BMS was not approved by the FDA due to angioedema safety concerns. … Omapatrilat is an investigational drug that inhibits both neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE).
LS11
go.drugbank.com/drugs/DB05918InvestigationalLS11(talaporfin sodium) is an agent consisting of chlorin e6, derived from chlorophyll, and L-aspartic acid with photosensitizing activity. … After intratumoral activation by light emitting diodes, taporfin sodium forms an extended high energy conformational state that generates singlet oxygen, resulting in free radical-mediated cell death.
CERE-110
go.drugbank.com/drugs/DB05898InvestigationalCERE-110 is a gene-therapy product that involves in vivo delivery of nerve growth factor (NGF) genes through an adeno-associated viral vector (AAV) delivery system.
Diosmetin
go.drugbank.com/drugs/DB11259ApprovedDiosmetin is an O-methylated flavone and the aglycone part of the flavonoid glycosides diosmin that occurs naturally in citrus fruits [A27231].
Pilaralisib
go.drugbank.com/drugs/DB11772InvestigationalPilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K).
Lumefantrine co-artemether
go.drugbank.com/drugs/DB13085ApprovedInvestigationalWithdrawnThe combination is an effective and well-tolerated malaria treatment, providing high cure rates even in areas of multi-drug resistance. … The exact mechanism of action of lumefantrine is not well defined, but it is thought to inhibit -hematin formation, an important detoxification pathway for the parasite.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesAzetukalner
go.drugbank.com/drugs/DB21551InvestigationalAzetukalner is under investigation in clinical trial NCT05718817 (An Open-label Study of XEN1101 in Epilepsy). Azetukalner has a monoisotopic molecular weight of 368.23 Da.